Nascent Biotech (NBIO) 10-Q 13 Aug 19 2019 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Jun. 30, 2019	Aug. 13, 2019
Document And Entity Information
Entity Registrant Name	Nascent Biotech Inc.
Entity Central Index Key	0001622057
Document Type	10-Q
Amendment Flag	false
Current Fiscal Year End Date	--03-31
Entity Small Business	true
Entity Shell Company	false
Entity Emerging Growth Company	false
Entity Current Reporting Status	Yes
Document Period End Date	Jun. 30, 2019
Entity Filer Category	Non-accelerated Filer
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2019
Entity Common Stock Shares Outstanding		33,495,470

CONSOLIDATED BALANCE SHEETS (Un

CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($)	Jun. 30, 2019	Mar. 31, 2019
Current assets:
Cash	$ 5,378	$ 131,472
Total current assets	5,378	131,472
Total assets	5,378	131,472
Current liabilities:
Accounts payable and accrued liabilities	606,344	525,636
Due to related parties	19,594	88,000
Total current liabilities	625,938	613,636
Total liabilities	625,938	613,636
Stockholders' deficit:
Preferred stock, $0.001 par value, 10,000,000 authorized, none issued and outstanding
Common stock, $0.001 par value; 100,000,000 authorized, 33,495,470 and 32,646,635 issued and outstanding, respectively	33,496	32,647
Additional paid-in capital	12,453,178	12,318,685
Accumulated deficit	(13,107,234)	(12,833,496)
Total stockholders' deficit	(620,560)	(482,164)
Total liabilities and stockholder' deficit	$ 5,378	$ 131,472

CONSOLIDATED BALANCE SHEETS (_2

CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) - $ / shares	Jun. 30, 2019	Mar. 31, 2019
Stockholders' deficit
Preferred stock, shares par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, shares par value	$ 0.001	$ 0.001
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	33,495,470	32,646,635
Common stock, shares outstanding	33,495,470	32,646,635

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($)	3 Months Ended
	Jun. 30, 2019	Jun. 30, 2018
Operating expenses
General and administrative expense	$ 244,951	$ 327,788
Research and development	28,792	111,939
Loss from operations	(273,743)	(439,727)
Other income (expense):
Interest income	5	8
Total other income (expense)	5	8
Net loss	$ (273,738)	$ (439,719)
Net loss per share, basic and diluted	$ (0.01)	$ (0.02)
Weighted average number of shares outstanding, basic and diluted	32,855,287	28,164,587

CONSOLIDATED STATEMENTS OF STOC

CONSOLIDATED STATEMENTS OF STOCKHOLDERS DEFICIT - USD ($)	Total	Common Stock Shares	Additional Paid-In Capital	Accumulated Deficit
Beginning balance, shares at Mar. 31, 2018		27,753,365
Beginning Balance, amount at Mar. 31, 2018	$ (86,379)	$ 27,754	$ 11,350,456	$ (11,464,589)
Common stock and warrants issued for cash, shares		271,428
Common stock issued to related parties for service, shares		87,788
Common stock issued for warrant exercise, shares		360,714
Common stock issued for service, shares		70,000
Option expense, amount	9,600		9,600
Net loss	(439,719)			(439,719)
Common stock and warrants issued for cash, amount	95,000	271	94,729
Common stock issued to related parties for service, amount	43,895	88	43,807
Common stock issued for warrant exercise, amount	18,035	361	17,674
Common stock issued for service, amount	27,500	$ 70	27,430
Ending Balance, shares at Jun. 30, 2018		28,543,295
Ending Balance, amount at Jun. 30, 2018	(332,068)	$ 28,544	11,543,696	(11,904,308)
Beginning balance, shares at Mar. 31, 2019		32,646,635
Beginning Balance, amount at Mar. 31, 2019	(482,164)	$ 32,647	12,318,685	(12,833,496)
Common stock issued to related parties for service, shares		137,872
Common stock issued for warrant exercise, shares		21,427
Common stock issued for service, shares		50,000
Option expense, amount
Net loss	(273,738)			(273,738)
Common stock issued related parties for AP settlement, shares		639,536
Common stock issued to related parties for service, amount	25,721	$ 138	25,583
Common stock issued for warrant exercise, amount	1,071	21	1,050
Common stock issued for service, amount	9,550	50	9,500
Common stock issued related parties for AP settlement, amount	99,000	$ 640	98,360
Ending Balance, shares at Jun. 30, 2019		33,495,470
Ending Balance, amount at Jun. 30, 2019	$ (620,560)	$ 33,496	$ 12,453,178	$ (13,107,234)

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($)	3 Months Ended
	Jun. 30, 2019	Jun. 30, 2018
Cash flows from operating activities
Net loss	$ (273,738)	$ (439,719)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation	35,271	71,394
Option expense		9,600
Changes in operating assets and liabilities:
Accounts payable and accrued expenses	80,708	155,836
Due to related parties	30,594	22,000
Net cash used in operating activities	(127,165)	(180,889)
Cash flows from financing activities:
Common stock issued for exercise of warrants	1,071	18,036
Proceeds from sale of common stock and warrants		95,000
Net cash provided by financing activities	1,071	113,036
Net decrease in cash	(126,094)	(67,853)
Cash -beginning of year	131,472	116,994
Cash -end of period	5,378	49,141
SUPPLEMENT DISCLOSURES:
Interest paid
Income taxes paid
Non Cash Transactions
Common stock issued for accrued expenses- related party	$ 99,000

ORGANIZATION AND NATURE OF OPER

ORGANIZATION AND NATURE OF OPERATIONS	3 Months Ended
	Jun. 30, 2019
ORGANIZATION AND NATURE OF OPERATIONS
NOTE 1 - ORGANIZATION AND NATURE OF OPERATIONS	Nascent Biotech, Inc. (Nascent or the Company) was incorporated on March 3, 2014 under the laws of the State of Nevada. The Company is actively developing its primary asset Pritumumab for the treatment of brain cancer and pancreatic cancer. Nascent is also actively researching other cancers that have a high probability of benefiting from the therapeutic effects of Pritumumab because they share a common target. Pritumumab has shown to be very effective at low doses in previous clinical studies in Japan. Nascent is a pre-clinical stage biopharmaceutical company that focuses on biologic drug candidates that are preparing for initial clinical testing for the treatment of brain and pancreatic cancer. On March 31, 2017 the Company filed its IND submission with the Federal Drug Administration (FDA) for clearance to begin Phase I clinical trials. On December 7, 2018 the Company received a letter from the FDA allowing it to use a specific lot of drug substance to begin phase 1 clinical trials. The FDA also requested additional data to remove the partial clinical hold. The Company is responding to additional data requests from the FDA requiring additional testing of the product and additional materials to answer specific questions from the FDA. The Company is negotiating with a clinical cancer center to begin clinical trials on brain cancer patients this fall.

BASIS OF PRESENTATION

BASIS OF PRESENTATION	3 Months Ended
	Jun. 30, 2019
BASIS OF PRESENTATION
NOTE 2 - BASIS OF PRESENTATION	The accompanying consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles. The Company has elected a fiscal year ending on March 31. The accompanying unaudited interim consolidated financial statements of the Company for the three months ended June 30, 2019 and 2018 have been prepared in accordance with accounting principles generally accepted in the United States for interim financial information in accordance with Securities and Exchange Commission and should be read in conjunction with the audited financial statements and notes thereto contained in the Companys annual report on Form 10-K for the year ended March 31, 2019. In the opinion of management, the unaudited financial statements have been prepared on the same basis as the annual financial statements and reflect all adjustments, which include only normal recurring adjustments, necessary to present fairly the financial position and the results of operations for the interim periods presented herein. The results of operations for the interim periods are not necessarily indicative of the results to be expected for any subsequent quarters or for an entire year. Recent Accounting Pronouncements In February 2016, the FASB issued ASU No. 2016-02, Leases. The main provisions of ASU No. 2016-02 require management to recognize lease assets and lease liabilities for all leases. ASU 2016-02 retains a distinction between finance leases and operating leases. The classification criteria for distinguishing between finance leases and operating leases are substantially similar to the classification criteria for distinguishing between capital leases and operating leases in the previous releases guidance. The result of retaining a distinction between finance leases and operating leases is that under the lessee accounting model, the effect of leases in the statement of comprehensive income and the statement of cash flows is largely unchanged from previous U.S. GAAP. The amendments in this ASU are effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. The adoption of this standard did not have a material impact on the Companys consolidated financial statements and related disclosures.

GOING CONCERN

GOING CONCERN	3 Months Ended
	Jun. 30, 2019
GOING CONCERN
NOTE 3 - GOING CONCERN	The Companys consolidated financial statements are prepared using accounting principles generally accepted in the United States of America applicable to a going concern that contemplates the realization of assets and liquidation of liabilities in the normal course of business. The Company has a working capital deficit and has incurred losses from operations. The Company has no revenue to cover its operating costs and the Company will incur additional expenses in the future developing their product. These factors raise substantial doubt about the companys ability to continue as a going concern. The Company engages in research and development activities that must be satisfied in cash secured through outside funding. The Company may offer noncash consideration and seek equity lines as a means of financing its operations. If the Company is unable to obtain revenue producing contracts or financing or if the revenue or financing it does obtain is insufficient to cover any operating losses it may incur, it may substantially curtail or terminate its operations or seek other business opportunities through strategic alliances, acquisitions or other arrangements that may dilute the interests of existing stockholders. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

RELATED PARTY TRANSACTIONS

RELATED PARTY TRANSACTIONS	3 Months Ended
	Jun. 30, 2019
RELATED PARTY TRANSACTIONS
NOTE 4 - RELATED PARTY TRANSACTIONS	On September 1, 2015, the Company entered five-year employment contracts with three of its officers and directors. Under the terms of the agreements the Company issued shares of common stock to the officers and directors equaling 11% of the outstanding shares of the Company as of the date of the contracts. As additional future shares are issued, the officers and directors are entitled to additional shares so their aggregate ownership percentage remains at 11% of the outstanding shares of the Company. The following table sets forth the shares earned under these contracts as of June 30, 2019: Officer and Director Initial Share Awards Under the Contracts Additional Shares Earned to Maintain Ownership Percentage Total Shares Earned President 1,028,910 668,976 1,697,886 Chief Financial Officer 617,346 404,193 1,021,539 Executive Vice President 617,346 404,193 1,021,539 Total 2,263,602 1,477,362 3,740,964 In addition, if the officers and directors are removed from the Company, they are entitled to receive a cash severance payment per annum for each year of the term of the contract less salary payments received to date of termination. The table below sets forth the annual salary and annual severance amounts per the contracts: Officer and Director Fiscal Year Annualized Compensation Being Paid Annual Severance per Contract if Terminated President $ 186,000 $ 250,000 Chief Financial Officer $ 132,000 $ 180,000 Executive Vice President $ 84,000 $ 140,000 Total $ 402,000 $ 570,000 During the three month period ended June 30, 2018 the Company issued 87,788 shares of common stock to three officers of the Company with a value of $43,895 for service. On June 5, 2019, two officers and directors of the Company converted $99,000 of accrued fees into 639,536 shares of common stock at $0.1548 per share. On June 28, 2019 the Company issued 137,872 shares of common stock to three officers and a director for service with a value of $25,721 During the three month period ended June 30, 2019 the Company paid a related party (officer and director) $6,000 of consulting fees in cash and accrued $15,000 of the consulting fees for a total of $21,000. During the three months period ended June 30, 2019, Company paid a related party and Chairman of the Scientific Board $4,000 of consulting fees in cash and accrued $2,000 of the fees with a total outstanding accrual of $9,000. During the same period in 2018, Company paid a related party and Chairman of the Scientific Board $9,000 in consulting fees and accrued $6,000 of the fees. As of June 30, 2019 the Company accrued $14,000 of compensation earned but not paid and $5,594 in expenses due to related parties.

COMMON STOCK

COMMON STOCK	3 Months Ended
	Jun. 30, 2019
COMMON STOCK
NOTE 5 - COMMON STOCK	During the three month period ended June 30, 2018 the Company issued 87,788 shares of common stock to three officers of the Company with a value of $43,895 for service. During the three month period ended June 30, 2018 the Company issued 360,714 shares of common stock to three warrant holders of the Company with a value of $18,035 for the exercise of 360,714 warrants. During the three month period ended June 30, 2018 the Company issued 70,000 shares of common stock of the Company to two individuals with a value of $27,500 for service. During the three month period ended June 30, 2018 the Company issued 271,428 shares of common stock and 121,329 warrants of the Company for cash of $95,000. On June 5, 2019, two officers and directors of the Company converted $99,000 of accrued fees into 639,536 shares of common stock at $0.1548 per share. During June 2019, two warrant holders exercised 21,427 warrants for common stock at $0.05 per share for cash of $1,071. On June 14, 2019 the Company issued 50,000 share of common stock to one individual with a value of $9,550 for service. On June 28, 2019 the Company issued 137,872 shares of common stock to three officers and a director for service with a value of $25,721.

OPTIONS

OPTIONS	3 Months Ended
	Jun. 30, 2019
OPTIONS
NOTE 6 - OPTIONS	As of June 30, 2019 there was no option expenses recognized by the Company and the balance of unrecognized option expense was zero. The following sets forth the options granted and outstanding during the three months ended June 30, 2019: Options Weighted Average Exercise Price Weighted Average Remaining Contract Life Number of Options Exercisable Intrinsic Value Outstanding at March 31, 2019 1,405,000 $ 0.34 6.80 1,397,000 $ -- Granted -- -- -- -- -- Exercised -- -- -- -- -- Outstanding at June 30, 2019 1,405,000 $ 0.34 6.55 1,397,000 $ -- The weighted average remaining life and intrinsic value of the options as of June 30, 2019, was 6.55 years and zero, respectively.

WARRANTS

WARRANTS	3 Months Ended
	Jun. 30, 2019
WARRANTS
NOTE 7 - WARRANTS	During the three month period ended June 30, 2018, the Company issued 121,329 warrants with each warrant is exercisable, within one year of the issuance, into one share of the Companys common stock at $0.05 per share. During the three month period ended June 30, 2018 three individual exercised 360,714 warrants into 360,714 shares of common stock with a value of $18,036 in cash. As of June 30, 2018, the Company had total outstanding warrants of 1,700,409. During the three months ended June 30, 2019 two individuals exercised 21,427 warrants into 21,427 shares of common stock for cash of $1,071. As of June 30, 2019 the Company had a total of 109,276 warrants outstanding. During the three months ended June 30, 2019 107,044 warrants expired. The weighted average remaining life and intrinsic value of the warrants as of June 30, 2019 was 0.08 years and zero respectively. Weighted Weighted Average Average Remaining Exercise Contract Intrinsic Warrants Price Life Value Outstanding at March 31, 2019 237,747 $ 0.20 0.25 $ 18,470 Granted -- -- -- -- Exercised (21,427 ) 0.05 -- -- Expired (107,044 ) (0.05 ) -- -- Outstanding at June 30, 2019 109,276 $ 0.37 0.08 $ --

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	3 Months Ended
	Jun. 30, 2019
COMMITMENTS AND CONTINGENCIES
NOTE 8 - COMMITMENTS AND CONTINGENCIES	On September 30, 2016, the Company entered a cell line sales agreement with the product manufacturer. Under the terms of the agreement the Company is obligated to make future payments based on the milestones of its achievements. These future payments may be as followed; 1. $100,000 upon the initiation (first dose/first patient) of the first Phase I clinical trial (or equivalent) of a Product; 2. $225,000 upon the initiation (first dose/first patient) of the first Phase III clinical trial (or equivalent) of a Product 3. $225,000 payable upon the first Biologics License Application approval (or equivalent) of a product. 4. Annual maintenance fee upon completion of phase I manufacturing or the transfer of the cell line from Catalent’s control of $50,000; 5. A contingent sales fee upon first commercial sale of a product of 1% of sales or $150,000 whichever is greater payable quarterly. As of June 30, 2019 $50,000 was due for the annual maintenance fee.

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	3 Months Ended
	Jun. 30, 2019
SUBSEQUENT EVENTS
NOTE 9 - SUBSEQUENT EVENTS	On July 10, 2019 the Company filed an amended articles of Incorporation designating 1,500,000 shares of preferred stock as Series A Convertible preferred shares convertible into common stock. As of July 11, 2019 109,276 warrants outstanding expired leaving zero warrant available for conversion. On July 11, 2019 an officer and director of the Company advanced the Company $10,000. The advance is on demand and bears no interest. On July 25, 2019 the Company issued 110,000 shares of series A convertible preferred to one entity with a value of $110,000 for cash. Each share of series A preferred is convertible after 180 days to four shares of common stock or at the lowest of: (i) the fixed conversion price; (ii) the equitant of 70% of the lowest closing price for the 20 days prior to the conversion of the preferred shares. On July 26, 2019 the Company repaid the $10,000 advance to the officer and director of the Company. On August 9, 2019 the Company signed a contract for clinical phase 1 studies with west coast clinic.

BASIS OF PRESENTATION (Policies

BASIS OF PRESENTATION (Policies)	3 Months Ended
	Jun. 30, 2019
BASIS OF PRESENTATION
Recent Accounting Pronouncements	In February 2016, the FASB issued ASU No. 2016-02, Leases. The main provisions of ASU No. 2016-02 require management to recognize lease assets and lease liabilities for all leases. ASU 2016-02 retains a distinction between finance leases and operating leases. The classification criteria for distinguishing between finance leases and operating leases are substantially similar to the classification criteria for distinguishing between capital leases and operating leases in the previous releases guidance. The result of retaining a distinction between finance leases and operating leases is that under the lessee accounting model, the effect of leases in the statement of comprehensive income and the statement of cash flows is largely unchanged from previous U.S. GAAP. The amendments in this ASU are effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. The adoption of this standard did not have a material impact on the Companys consolidated financial statements and related disclosures.

RELATED PARTY TRANSACTIONS (Tab

RELATED PARTY TRANSACTIONS (Tables)	3 Months Ended
	Jun. 30, 2019
RELATED PARTY TRANSACTIONS (Tables)
Contracts shares earned	Officer and Director Initial Share Awards Under the Contracts Additional Shares Earned to Maintain Ownership Percentage Total Shares Earned President 1,028,910 668,976 1,697,886 Chief Financial Officer 617,346 404,193 1,021,539 Executive Vice President 617,346 404,193 1,021,539 Total 2,263,602 1,477,362 3,740,964
Annual salary and annual severance amounts per the contracts of related party	Officer and Director Fiscal Year Annualized Compensation Being Paid Annual Severance per Contract if Terminated President $ 186,000 $ 250,000 Chief Financial Officer $ 132,000 $ 180,000 Executive Vice President $ 84,000 $ 140,000 Total $ 402,000 $ 570,000

OPTIONS (Tables)

OPTIONS (Tables)	3 Months Ended
	Jun. 30, 2019
OPTIONS (Tables)
Summary of stock options and warrants outstanding	Options Weighted Average Exercise Price Weighted Average Remaining Contract Life Number of Options Exercisable Intrinsic Value Outstanding at March 31, 2019 1,405,000 $ 0.34 6.80 1,397,000 $ -- Granted -- -- -- -- -- Exercised -- -- -- -- -- Outstanding at June 30, 2019 1,405,000 $ 0.34 6.55 1,397,000 $ --

WARRANTS (Tables)

WARRANTS (Tables)	3 Months Ended
	Jun. 30, 2019
WARRANTS (Tables)
Summary of stock options and warrants outstanding	Weighted Weighted Average Average Remaining Exercise Contract Intrinsic Warrants Price Life Value Outstanding at March 31, 2019 237,747 $ 0.20 0.25 $ 18,470 Granted -- -- -- -- Exercised (21,427 ) 0.05 -- -- Expired (107,044 ) (0.05 ) -- -- Outstanding at June 30, 2019 109,276 $ 0.37 0.08 $ --

ORGANIZATION AND NATURE OF OP_2

ORGANIZATION AND NATURE OF OPERATIONS (Details Narrative)	3 Months Ended
	Jun. 30, 2019
ORGANIZATION AND NATURE OF OPERATIONS (Details Narrative)
Date of Incorporation	Mar. 3, 2014
State of Incorporation	Nevada

RELATED PARTY TRANSACTIONS (Det

RELATED PARTY TRANSACTIONS (Details)	3 Months Ended
	Jun. 30, 2019shares
Initial Share Awards Under the Contracts	2,263,602
Additional Shares Earned to Maintain Ownership Percentage	1,477,362
Total Shares Earned	3,740,964
President [Member]
Initial Share Awards Under the Contracts	1,028,910
Additional Shares Earned to Maintain Ownership Percentage	668,976
Total Shares Earned	1,697,886
Chief Financial Officer [Member]
Initial Share Awards Under the Contracts	617,346
Additional Shares Earned to Maintain Ownership Percentage	404,193
Total Shares Earned	1,021,539
Executive Vice President [Member]
Initial Share Awards Under the Contracts	617,346
Additional Shares Earned to Maintain Ownership Percentage	404,193
Total Shares Earned	1,021,539

RELATED PARTY TRANSACTIONS (D_2

RELATED PARTY TRANSACTIONS (Details 1)	3 Months Ended
	Jun. 30, 2019USD ($)
Fiscal year annualized compensation being paid	$ 402,000
Annual Severance per Contract if Terminated	570,000
President [Member]
Fiscal year annualized compensation being paid	186,000
Annual Severance per Contract if Terminated	250,000
Chief Financial Officer [Member]
Fiscal year annualized compensation being paid	132,000
Annual Severance per Contract if Terminated	180,000
Executive Vice President [Member]
Fiscal year annualized compensation being paid	84,000
Annual Severance per Contract if Terminated	$ 140,000

RELATED PARTY TRANSACTIONS (D_3

RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)	1 Months Ended		3 Months Ended
	Jun. 28, 2019	Jun. 05, 2019	Jun. 30, 2019	Jun. 30, 2018
Accrued compensation			$ 14,000
Due to related parties			5,594
Common shares issued for services, value			9,550	27,500
Related party and Chairman of the Scientific Board [Member]
Consulting fees, paid			4,000	9,000
Accrued consulting fees			2,000	$ 6,000
Total consulting fees			9,000
Two Officers And Directors [Member]
Amount of accrued fees converted		$ 99,000
Common stock shares issued upon conversion of accrued fees		639,536
Conversion price		$ 0.1548
Officer and Director [Member]
Consulting fees, paid			6,000
Accrued consulting fees			15,000
Total consulting fees			$ 21,000
Three Officers [Member]
Common shares issued for services, shares				87,788
Common shares issued for services, value				$ 43,895
Three Officers And Director [Member]
Common shares issued for services, shares	137,872
Common shares issued for services, value	$ 25,721
Three Officers And Director [Member] | September 1, 2015 [Member]
Officers and directors employment agreement terms, description			the Company entered five-year employment contracts with three of its officers and directors. Under the terms of the agreements the Company issued shares of common stock to the officers and directors equaling 11% of the outstanding shares of the Company as of the date of the contracts. As additional future shares are issued, the officers and directors are entitled to additional shares so their aggregate ownership percentage remains at 11% of the outstanding shares of the Company.

COMMON STOCK (Details Narrative

COMMON STOCK (Details Narrative) - USD ($)	Jun. 14, 2019	Jun. 30, 2019	Jun. 28, 2019	Jun. 05, 2019	Jun. 30, 2019	Jun. 30, 2018
Common shares issued, shares						271,428
Class of warrants or rights issued						121,329
Common stock and warrants issued, value						$ 95,000
Common shares issued for services, amount					$ 9,550	27,500
Two warrant holders [Member]
Proceeds from exercise of warrants		$ 1,071
Exercise price of warrants		$ 0.05
Warrants exercised		21,427
Warrant [Member]
Warrants exercised						360,714
Common shares issued upon exercise of warrants						360,714
Common shares issued upon exercise of warrants, value						$ 18,035
Two Officers And Directors [Member]
Amount of accrued fees converted				$ 99,000
Conversion price				$ 0.1548
Common stock shares issued upon conversion of accrued fees				639,536
Three Officers [Member]
Common shares issued for services, shares						87,788
Common shares issued for services, amount						$ 43,895
Two individual [Member]
Common shares issued for services, shares	50,000					70,000
Common shares issued for services, amount	$ 9,550					$ 27,500
Three Officers And Director [Member]
Common shares issued for services, shares			137,872
Common shares issued for services, amount			$ 25,721
One Individuals [Member]
Common shares issued for services, shares	50,000
Common shares issued for services, amount	$ 9,550

OPTIONS (Details)

OPTIONS (Details)	3 Months Ended
	Jun. 30, 2019USD ($)$ / sharesshares
Weighted average remaining contract life, Ending	6 years 6 months 18 days
Options [Member]
Outstanding option/warrants, Beginning	1,405,000
Option granted
Option exercised
Outstanding option/warrants, Ending	1,405,000
Weighted average exercise price, Beginning | $ / shares	$ 0.34
Granted | $ / shares
Exercised | $ / shares
Weighted average exercise price, Ending | $ / shares	$ 0.34
Weighted average remaining contract life, Beginning	6 years 9 months 18 days
Weighted average remaining contract life granted
Weighted average remaining contract life, Ending	6 years 6 months 18 days
Number of options exercisable Beginning balance	1,397,000
Granted
Exercised
Number of options exercisable ending balance	1,397,000
Intrinsic value, Beginning | $
Granted | $
Exercised | $
Intrinsic value, Ending | $

OPTIONS (Details Narrative)

OPTIONS (Details Narrative)	3 Months Ended
	Jun. 30, 2019USD ($)
OPTIONS (Details Narrative)
Weighted average remaining contract life, Ending	6 years 6 months 18 days
Weighted average intrinsic value	$ 0

WARRANTS (Details)

WARRANTS (Details) - Warrant [Member]	3 Months Ended
	Jun. 30, 2019USD ($)$ / sharesshares
Outstanding option/warrants, Beginning | shares	237,747
Warrants granted, shares | shares
Warrants exercised, shares | shares	(21,427)
Warrants expired, shares | shares	(107,044)
Outstanding option/warrants, Ending | shares	109,276
Weighted average exercise price, Beginning | $ / shares	$ 0.20
Granted | $ / shares
Exercised | $ / shares	0.05
Expired | $ / shares	(0.05)
Weighted average exercise price, Ending | $ / shares	$ 0.37
Weighted average remaining contract life, Beginning	3 months
Weighted average remaining contract life, Ending	24 days
Intrinsic value, Beginning | $	$ 18,470
Granted | $
Exercised | $
Intrinsic value expired | $
Intrinsic value, Ending | $

WARRANTS (Details Narrative)

WARRANTS (Details Narrative) - USD ($)	1 Months Ended	3 Months Ended
	Jun. 30, 2019	Jun. 30, 2019	Jun. 30, 2018	Mar. 31, 2019
Warrant [Member]
Warrants exercisable period		1 year
Warrants exercised		(21,427)	360,714
Warrants issued, shares		121,329
Exercise price of warrants		$ 0.05
Common shares issued upon exercise of warrants, value			$ 18,035
Common shares issued upon exercise of warrants			360,714
Weighted average remaining contract life		28 days
Intrinsic value		$ 0
Outstanding warrants	109,276	109,276	1,700,409	237,747
Warrants expired, shares		(107,044)
Two warrant holders [Member]
Warrants exercised	21,427
Proceeds from exercise of warrants	$ 1,071
Exercise price of warrants	$ 0.05

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)	3 Months Ended
	Jun. 30, 2016	Jun. 30, 2019	Sep. 30, 2016
Contingent sales fee description	A contingent sales fee upon first commercial sale of a product of 1% of sales or $150,000 whichever is greater payable quarterly.
Annual maintenance fee payable		$ 50,000
First Phase I clinical trial [Member]
Future payments			100,000
Annual maintenance fee			50,000
First Phase III clinical trial [Member]
Future payments			225,000
First Biologics License [Member]
Future payments			$ 225,000

SUBSEQUENT EVENTS (Details Narr

SUBSEQUENT EVENTS (Details Narrative) - USD ($)	Jul. 11, 2019	Jul. 26, 2019	Jul. 25, 2019	Jun. 30, 2019	Jun. 30, 2018	Jul. 10, 2019	Mar. 31, 2019
Preferred stock shares authorized				10,000,000			10,000,000
Common shares issued for services, amount				$ 9,550	$ 27,500
Subsequent Event [Member]
Warrants expired, shares	(109,276)
Subsequent Event [Member] | Officer and Director [Member]
Repayment of related party debt		$ 10,000
Due to related party	$ 10,000
Subsequent Event [Member] | SeriesA Convertible Preferred [Member]
Preferred stock shares authorized						1,500,000
Common shares issued for services, shares			110,000
Common shares issued for services, amount			$ 110,000
Terms of conversion feature			Each share of series A preferred is convertible after 180 days to 4 shares of common stock or at the lowest of: (i) the fixed conversion price; (ii) the equitant of 70% of the lowest closing price for the 20 days prior to the conversion of the preferred shares